4-hydroxytetrahydropyran-3-sulfonamide | 1398606-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 4-hydroxytetrahydropyran-3-sulfonamide
• 英文别名: 4-hydroxyoxane-3-sulfonamide
• CAS: 1398606-44-4
• 化学式: C₅H₁₁NO₄S
• 分子量: 181.213
• InChiKey: DPLRBFQCOBTMFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  98
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-hydroxytetrahydropyran-3-sulfonamide 在 N-溴代丁二酰亚胺(NBS) 、 potassium tert-butylate 作用下， 反应 0.24h， 生成 、
  参考文献：
  名称：

  1,1-Dioxo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11ß-HSD1 inhibitors for the treatment of diabetes

  摘要：

  Racemic cis-1,1-dioxo-5,6-dihydro-[4,1,2]oxathiazine derivative 4a was isolated as an impurity in a sample of a hit from a HTS campaign on 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). After separation by chiral chromatography the 4a-S, 8a-R enantiomer of compound 4a was identified as the true, potent enzyme inhibitor. The cocrystal structure of 4a with human and murine 11 beta-HSD1 revealed the unique binding mode of the oxathiazine series. SAR elucidation and optimization in regard to metabolic stability led to monocyclic tetramethyloxathiazines as exemplified by compound 21g. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.102
• 作为产物：
  描述：

  四氢吡喃酮 在 sodium tetrahydroborate 、 氨基磺酰氯 、 二异丙胺 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 25.0h， 生成 4-hydroxytetrahydropyran-3-sulfonamide
  参考文献：
  名称：

  OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF

  摘要：

  这项发明涉及公式(I)的化合物及其生理上可接受的盐。这些化合物适用于治疗高血糖等疾病。

  公开号：

  US20130345128A1

文献信息

• [EN] TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE FURANE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018097944A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

  式(I)和式(II)的化合物，其药用盐，任何上述化合物的立体异构体，或它们的混合物是APJ受体的激动剂，并且在治疗心血管和其他疾病方面有用。式(I)和式(II)的化合物具有以下结构：(I); (II)。中间体(V)也被要求。
• BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF
  申请人：Boehme Thomas

  公开号：US20130345126A1

  公开（公告）日：2013-12-26

  The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.

  该发明涉及公式(I)的化合物及其生理相容盐。所述化合物适用于治疗高血糖，例如。
• Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
  申请人：Boehme Thomas

  公开号：US08901114B2

  公开（公告）日：2014-12-02

  The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia.

  本发明涉及公式（I）的化合物及其生理上可接受的盐。该化合物适用于治疗高血糖等疾病。
• Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
  申请人：Boehme Thomas

  公开号：US08828995B2

  公开（公告）日：2014-09-09

  The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.

  本发明涉及式(I)的化合物及其生理兼容盐。该化合物适用于治疗高血糖等疾病。